Last $3.15 USD
Change Today -0.03 / -0.94%
Volume 59.3K
OGXI On Other Exchanges
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

oncogenex pharmaceutical inc (OGXI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - $14.25
52 Week Low
07/22/14 - $3.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

oncogenex pharmaceutical inc (OGXI) Related Businessweek News

No Related Businessweek News Found

oncogenex pharmaceutical inc (OGXI) Details

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. Its lead drug candidate, Custirsen is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, and in patients with advanced, unresectable non-small cell lung cancer. Custirsen is an experimental drug designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. The company also develops Apatorsen, which is in seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers. Apatorsen is an investigational drug designed to inhibit the production of heat shock protein (Hsp27), a protein that is elevated in various cancers and that has been shown to promote cancer cell growth and tumor metastasis. In addition, it develops OGX-225 that is in pre-clinical development for the treatment of solid tumors. The company has a collaboration and license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize Custirsen. The company is headquartered in Bothell, Washington.

37 Employees
Last Reported Date: 03/11/14

oncogenex pharmaceutical inc (OGXI) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $503.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $403.1K
Compensation as of Fiscal Year 2013.

oncogenex pharmaceutical inc (OGXI) Key Developments

OncoGenex Pharmaceuticals, Inc. Announces Initiation of Cedar Clinical Trial

OncoGenex Pharmaceuticals, Inc. announced initiation of the Cedar(TM) clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer. Apatorsen is a once-weekly intravenous (IV) experimental drug that is designed to inhibit production of heat shock protein 27 (Hsp27) to disable cancer cells defenses and overcome treatment resistance. Approximately 140 patients with previously untreated stage IV or recurrent squamous cell lung cancers or stage IIIB squamous cell cancers that are not amenable to radiochemotherapy will be randomized to receive either apatorsen plus gemcitabine and carboplatin therapy, or gemcitabine and carboplatin therapy alone. The primary objective is progression-free survival (PFS), with secondary objectives to evaluate tumor response rates, overall survival, safety, tolerability, and health-related quality of life. Additional analyses will be conducted to determine the effect of therapy on Hsp27 levels and to explore potential biomarkers that may help predict response to treatment. Cedar is an investigator-sponsored trial being conducted and funded primarily by the UK National Cancer Research Network and the UK Experimental Cancer Medicine Network and will involve approximately 20 centers in the United Kingdom.

OncoGenex Pharmaceuticals, Inc.(NasdaqCM:OGXI) dropped from Russell 2000 Index

OncoGenex Pharmaceuticals, Inc. will be removed from the Russell 2000 Index.

OncoGenex Pharmaceuticals, Inc.(NasdaqCM:OGXI) dropped from Russell 3000 Index

OncoGenex Pharmaceuticals, Inc. will be removed from the Russell 3000 Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGXI:US $3.15 USD -0.03

OGXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OGXI.
View Industry Companies

Industry Analysis


Industry Average

Valuation OGXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.3x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOGENEX PHARMACEUTICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at